Table 1. Clinical features of AML and... | American Society of Hematology

Table 1.

Clinical features of AML and MDS patients treated with decitabine

Patient no.	Sex	Age	Diagnosis	FAB	DAC mg/m²/day (× 3 days)	Previous treatment
1	F	65	de novo AML	M1	60	No*
2	F	83	de novo AML	M1	30	No
3	M	69	de novo AML	M1	90	No
4	F	60	de novo AML	M4	60	No
5	M	62	de novo AML	M4	60	No
6	F	62	de novo AML	M4	30	No
7	M	64	de novo AML	M5	30	No
8	M	74	Secondary AML†	M1	30	HU
9	F	79	MDS	AREB-t	15	No
10	M	72	MDS	AREB-t	15	No
11	M	67	MDS	CMMoL	15	No

Patient no.	Sex	Age	Diagnosis	FAB	DAC mg/m²/day (× 3 days)	Previous treatment
1	F	65	de novo AML	M1	60	No*
2	F	83	de novo AML	M1	30	No
3	M	69	de novo AML	M1	90	No
4	F	60	de novo AML	M4	60	No
5	M	62	de novo AML	M4	60	No
6	F	62	de novo AML	M4	30	No
7	M	64	de novo AML	M5	30	No
8	M	74	Secondary AML†	M1	30	HU
9	F	79	MDS	AREB-t	15	No
10	M	72	MDS	AREB-t	15	No
11	M	67	MDS	CMMoL	15	No

Decitabine was administrated at the indicated daily dosages, divided into three 4-hour infusions for 3 days.

DAC indicates decitabine; F, female; M, male; RAEB-t, refractory anemia with excess blasts in leukemic transformation; HU, hydroxyurea; and CMMoL, chronic myelomonocytic leukemia.

Decitabine was used as first-line therapy due to the low performance status (less than 60%, Karnofsky scale) of patients.

†

Secondary AMLs evolved from a previous myeloproliferative disorder.

View Large

This Feature Is Available To Subscribers Only